Business Context and Reporting Period
Company: Scinai Immunotherapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: September 2026
Date of Filing: September 21, 2026
This filing serves to disclose a corporate event regarding regulatory compliance with the Nasdaq stock exchange. The registrant files annual reports under Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is an informational report regarding a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
Nasdaq Compliance: On September 21, 2026, the company issued a press release stating it has regained compliance with the Nasdaq Minimum Bid Price Requirement. This indicates a resolution to a previous deficiency regarding the trading price of its securities.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release (Exhibit 99.1) titled "Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement." No specific forward-looking guidance, risk factors, or contingencies are detailed within the text of this specific Form 6-K.
Investor Verification Checklist
- Verify the current trading price of Scinai Immunotherapeutics Ltd. to confirm sustained compliance with Nasdaq listing standards.
- Review the full text of the press release (Exhibit 99.1) for details on the specific actions taken to regain compliance.
- Check for any prior Nasdaq deficiency notices to understand the duration and context of the non-compliance period.
- Confirm the company's status on the Nasdaq Capital Market or Global Market to ensure continued listing.